Channels
All News
In Focus
Special
AI
Bioregnum
Biotech Voices
Cell/Gene Tx
China
Coronavirus
Deals
Diagnostics
Discovery
FDA+
Financing
Health Tech
Law
Letters to the Editor
Manufacturing
Marketing
Nikkei Biotechnology
Opinion
Outsourcing
Peer Review
People
Pharma
R&D
Startups
Weekly
Webinars
Biopharma Jobs
More
Work at Endpoints
Letter to Editors
Editorial Standards
IPO Tracker
Webinars
Events
Sponsored Posts
Advertise
Privacy Policy
Endpoints Merch
About Us
Help
SIGN UP
LOG IN
In Focus channel feed
The coronavirus vaccine that the world forgot could still help save it
4 years ago
Coronavirus
As Bayer, Novartis stack up their radiopharmaceutical data at #ESMO21, a key debate takes shape
4 years ago
R&D
Inside the quixotic 30-year quest that gave us the Covid-19 treatments, vaccines and could unlock vaccinology’s new holy grail
4 years ago
'The consummate mentor': Bill Clinton, Jim Wilson and others reflect on Tachi Yamada's life and legacy
4 years ago
People
In CureVac's failure, a possible verdict on the past (and future) of mRNA vaccines
4 years ago
R&D
How one startup foretold the neuroscience renaissance after '50 years of shitshow'
4 years ago
R&D
On the hunt for the next Moderna, investors have pumped 'platform plays' with cash. Can anything slow the runaway train?
5 years ago
Financing
FDA's controversial Aduhelm decision leaves ALS patients feeling spurned
5 years ago
Pharma
Whatever the FDA decides on aducanumab, Alzheimer's research is finally, mostly, kind of moving beyond the amyloid hypothesis
5 years ago
R&D
A simple patient survey revolutionized ALS drug development in the 1990s. Its creator says it may be time for an upgrade
5 years ago
R&D
Researchers in biotech, academia and Big Pharma are offering puzzle pieces to crack CAR-T for solid tumors. Will they ever snap together?
5 years ago
Cell/Gene Tx
Inside Vertex 3.0: Can Reshma Kewalramani repeat one of biotech's biggest success stories 'again and again and again'?
5 years ago
People
As fears mount over J&J and AstraZeneca, Novavax enters a shaky spotlight
5 years ago
Coronavirus
Nearly a year after Audentes' gene therapy deaths, the trial continues. What happened remains a mystery
5 years ago
Cell/Gene Tx
'Part of recovery is awareness': Pandemic casts harsh spotlight on industry-wide lack of diversity in clinical trials
5 years ago
R&D
David Liu has a new big idea: proteome editing. It could one day shred tau, RAS and some of the worst disease-causing proteins
5 years ago
Discovery
Biopharma's success rate in bringing drugs to market has long been abysmal. Can new tools help rewrite that troubled past?
5 years ago
Exclusive: After four decades, one researcher's radical HIV cure finally gets its shot
5 years ago
People
Startups
After 3 deaths rock the field, gene therapy researchers contemplate AAV's future
5 years ago
Can a new CRISPR technique unlock the secrets of how cancer spreads?
5 years ago
Discovery
They thought their gene therapy failed. Instead, it spawned a medical mystery
5 years ago
Discovery
As the curtain closes on the Trump presidency, biotech wrestles with its future in a divided America
5 years ago
People
Can a darkhorse synthetic biology Covid-19 vaccine one-up the frontunners? The Gates Foundation, Amgen bet 'yes'
5 years ago
R&D
Coronavirus
After falling behind the leaders, dissed by some experts, biotech showman Patrick Soon-Shiong finally gets his Covid-19 vaccine ready for a trial. But can it live up to the hype?
5 years ago
People
Coronavirus
First page
Previous page
4
5
6
7
8
Next page
Last page